Category
Healthcare spending
Where the money goes, and what happens when it runs short. This coverage follows budgets, cost growth, pricing pressure and the trade-offs health systems make under them.
150 articles in this topic.
Articles in this category

10/27/2026
Novartis core operating income rises, 2026 outlook raised
Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess
Read Article →
10/26/2026
Obesity drug reimbursement in Portugal: new SNS terms
Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess
Read Article →
10/26/2026
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla's review succeeded on all five grounds, while Hetero's challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV
Read Article →
10/13/2026
Health Security in Europe: Why Resilience Starts Before a Crisis
Health security in Europe is being redefined from emergency response to national resilience, and the EFPIA View argues it starts with funded health systems.
Read Article →
10/13/2026
Health Investment Returns: What Berlin’s Funding the Future Panel Argued
Ministers, development banks and industry at the World Health Summit argued that health investment returns should be measured in lives saved, jobs and tax revenue, not budget size. #SyenzaNews #HealthEconomics #MarketAccess
Read Article →
10/12/2026
The Strategic Health Economy: Why Finance Ministries Still See Health as a Cost
At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics
Read Article →
10/7/2026
BD US Government Partnership Commits $19 Billion to US Manufacturing
BD has agreed a $19 billion partnership with the US Government to expand American manufacturing of essential medical consumables. The deal includes $3 billion for production sites, roughly 5 billion more units a year and Section 232 tariff relief tied to milestones. #SyenzaNews #MedTech #MarketAccess
Read Article →
10/6/2026
Transparency in Coverage Final Rule Rewrites US Payer Price Files
US group health plans and issuers must rebuild their public price files under the Transparency in Coverage final rule: quarterly publication, an 11-claim threshold for out-of-network data, a new utilization file and attestation, and consumer phone disclosure from January 2027. #SyenzaNews #MarketAccess #PriceTransparency #HEOR
Read Article →
9/3/2026
US healthcare market access: what four operators told Canadian healthtech founders
CTS's Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech
Read Article →
9/2/2026
Korea AI Basic Healthcare Strategy Targets Global Biohealth Leadership
South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess
Read Article →
9/1/2026
Portugal private health insurance premiums average €466 a year, up 9.1%
Portuguese private health insurers cleared €1 billion in six months as premiums climbed 9.1% to €466 a year. #SyenzaNews #HealthInsurance #Portugal #MarketAccess
Read Article →
9/1/2026
US Expands MFN Drug Pricing to 26 Manufacturers
The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma
Read Article →

